(Q37905881)

25 August 2017

1 reference

title

Systematic review: the pathophysiology and management of polycystic liver disease (English)

1 reference

25 August 2017

1 reference

1 reference

W Laleman

4

0 references

Bert Bammens

object named as

B Bammens

3

0 references

author name string

F Temmerman

1

1 reference

25 August 2017

L Missiaen

2

1 reference

25 August 2017

D Cassiman

5

1 reference

25 August 2017

C Verslype

6

1 reference

25 August 2017

J van Pelt

7

1 reference

25 August 2017

F Nevens

8

1 reference

25 August 2017

language of work or name

English

0 references

publication date

26 July 2011

1 reference

Alimentary Pharmacology & Therapeutics

25 August 2017

published in

1 reference

25 August 2017

volume

34

1 reference

25 August 2017

issue

7

1 reference

25 August 2017

page(s)

702-713

1 reference

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Liver transplantation for polycystic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Surgical management of polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Cholangiociliopathies: genetics, molecular mechanisms and potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Mutations in SEC63 cause autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Polycystic disease of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Molecular pathogenesis of ADPKD: the polycystin complex gets complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

TRPP2 and autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Emerging evidence of a link between the polycystins and the mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Clinical profile of autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

The cholangiopathies: disorders of biliary epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Primary cilia in normal and pathological tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

A physiological view of the primary cilium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

An incredible decade for the primary cilium: a look at a once-forgotten organelle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Cholangiocyte primary cilia in liver health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Regulation and deregulation of cholangiocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Matrix metalloproteinase activity in human intrahepatic biliary epithelial cell lines from patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Estrogens and the pathophysiology of the biliary tree

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

80K-H interacts with inositol 1,4,5-trisphosphate (IP3) receptors and regulates IP3-induced calcium release activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Loss of Inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Gastrin inhibits cholangiocyte growth in bile duct-ligated rats by interaction with cholecystokinin-B/Gastrin receptors via D-myo-inositol 1,4,5-triphosphate-, Ca(2+)-, and protein kinase C alpha-dependent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Sirolimus reduces polycystic liver volume in ADPKD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Medical and surgical treatment options for polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Obstructive jaundice associated with polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Isolated polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Laparoscopic management of benign liver diseases: where are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Hepatic cysts: treatment with alcohol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Role of nutrition in liver transplantation for end-stage chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

mTOR inhibitors in polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Treatment strategies and clinical trial design in ADPKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04783.X

10.1111/J.1365-2036.2011.04783.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference